8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial

F. Hammouch, J.F. Baurain, Laurette Renard, Vincent Verschaeve(Grand Charleroi Hospital), Tom Boterberg(Ghent University Hospital), E. Joosens(Jessa Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Daniel Devriendt, Nicolas Whenham(Cliniques Universitaires Saint-Luc)

European Journal of Cancer

September 1, 2011

10.1016/s0959-8049(11)72295-x

Cited by 1

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

|Journal of Clinical Oncology|2009|573

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

|The Lancet Oncology|2016|504

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

|Journal of Clinical Oncology|2010|445

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

|The Lancet|2017|401